Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$10.61
0.030.28%
Last update: May 18, 12:06 PM
Bioventus Inc Analyst Ratings
BVSNASDAQ
Bioventus Analyst Ratings and Price Targets | NASDAQ:BVS | Benzinga
Bioventus Inc has a consensus price target of $14.17 based on the ratings of 6 analysts. The high is $16 issued by Craig-Hallum on March 6, 2026. The low is $12 issued by Cantor Fitzgerald on July 7, 2025. The 3 most-recent analyst ratings were released by Barrington Research, Craig-Hallum, and Barrington Research on March 6, 2026, March 6, 2026, and February 9, 2026, respectively. With an average price target of $14.33 between Barrington Research, Craig-Hallum, and Barrington Research, there's an implied 35.09% upside for Bioventus Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barrington Research
Craig-Hallum
Cantor Fitzgerald
Canaccord Genuity
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Bioventus
Loading calendar...
FAQ
What is the target price for Bioventus (BVS) stock?
The latest price target for Bioventus (NASDAQ:BVS) was reported by Barrington Research on March 6, 2026. The analyst firm set a price target for $14.00 expecting BVS to rise to within 12 months (a possible 31.95% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bioventus (BVS)?
The latest analyst rating for Bioventus (NASDAQ:BVS) was provided by Barrington Research, and Bioventus maintained their outperform rating.
When was the last upgrade for Bioventus (BVS)?
The last upgrade for Bioventus Inc happened on December 17, 2024 when JP Morgan raised their price target to $13. JP Morgan previously had an underweight for Bioventus Inc.
When was the last downgrade for Bioventus (BVS)?
There is no last downgrade for Bioventus.
When is the next analyst rating going to be posted or updated for Bioventus (BVS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioventus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioventus was filed on March 6, 2026 so you should expect the next rating to be made available sometime around March 6, 2027.
Is the Analyst Rating Bioventus (BVS) correct?
While ratings are subjective and will change, the latest Bioventus (BVS) rating was a maintained with a price target of $13.00 to $14.00. The current price Bioventus (BVS) is trading at is $10.61, which is out of the analyst’s predicted range.
